Pacira BioSciences, Inc. (PCRX)
Profitability ratios
Return on sales
| Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross profit margin | 71.60% | 68.17% | 67.83% | 68.95% | 70.52% | 70.12% | 68.65% | 68.28% | 70.11% | 73.03% | 73.90% | 75.02% | 74.10% | 73.27% | 73.66% | 73.00% | 72.54% | 72.94% | 73.98% | 74.93% |
| Operating profit margin | -9.81% | -8.56% | 14.16% | 15.65% | 15.37% | 13.05% | 12.05% | 7.87% | 8.69% | 6.88% | 10.57% | 15.14% | 16.61% | 20.45% | 18.11% | 11.05% | 10.85% | 6.95% | 3.45% | 6.09% |
| Pretax margin | -9.00% | -7.90% | 14.57% | 14.93% | 9.14% | 1.49% | -0.69% | -3.06% | 1.99% | 3.85% | 7.71% | 8.78% | 10.42% | 14.74% | 11.43% | 5.51% | 4.70% | 0.92% | -1.99% | 0.08% |
| Net profit margin | -14.20% | -13.06% | 9.21% | 10.34% | 6.22% | 1.05% | -0.68% | -1.56% | 2.39% | 3.19% | 6.39% | 6.62% | 7.75% | 12.06% | 34.77% | 33.53% | 34.06% | 29.95% | -2.47% | -0.02% |
Pacira BioSciences, Inc.'s profitability ratios have shown fluctuations over the periods analyzed:
1. Gross Profit Margin: Pacira's gross profit margin has varied between 67.83% and 75.02% during the period. While there were fluctuations, the company has generally maintained a high gross profit margin, indicating efficient production and cost control.
2. Operating Profit Margin: The operating profit margin ranged from -9.81% to 20.45% over the period. There were significant fluctuations, with some periods showing negative margins. The company experienced a drop in profitability in September 2024, resulting in a negative operating profit margin.
3. Pretax Margin: Pacira's pretax margin fluctuated between -9.00% and 14.93% during the period. The company struggled with negative pretax margins in some periods but managed to achieve positive margins in others, with the highest recorded in March 2024.
4. Net Profit Margin: The net profit margin ranged from -14.20% to 34.77% over the period. Pacira saw fluctuations in net profitability, with negative margins in some quarters. The net profit margin showed improvement in the first half of the analyzed period but worsened towards the end of 2024.
Overall, Pacira BioSciences, Inc. has experienced fluctuations in its profitability ratios, with varying levels of success in generating profits from its operations. It is essential for the company to focus on maintaining and improving its profitability margins to ensure sustainable growth and shareholder value.
Return on investment
| Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating return on assets (Operating ROA) | -4.42% | -3.91% | 5.94% | 6.74% | 6.59% | 5.66% | 5.23% | 3.46% | 3.45% | 2.60% | 3.75% | 4.65% | 4.33% | 7.71% | 6.84% | 3.78% | 3.64% | 2.40% | 1.62% | 3.23% |
| Return on assets (ROA) | -6.41% | -5.96% | 3.86% | 4.45% | 2.66% | 0.46% | -0.30% | -0.69% | 0.95% | 1.20% | 2.26% | 2.03% | 2.02% | 4.54% | 13.13% | 11.47% | 11.42% | 10.34% | -1.16% | -0.01% |
| Return on total capital | -7.42% | -7.09% | 11.71% | 10.68% | 7.06% | 2.46% | 2.62% | 1.44% | 6.41% | 13.58% | 15.11% | 18.86% | 18.27% | 15.89% | 15.14% | 11.14% | 10.08% | 8.83% | 8.65% | 10.99% |
| Return on equity (ROE) | -12.79% | -12.10% | 7.23% | 7.90% | 4.82% | 0.84% | -0.57% | -1.36% | 2.05% | 2.71% | 5.19% | 5.42% | 5.75% | 8.58% | 25.33% | 22.70% | 23.48% | 21.57% | -2.60% | -0.02% |
Pacira BioSciences, Inc.'s profitability ratios show relatively mixed performance over the periods analyzed.
- Operating return on assets (Operating ROA), which measures operating income generated per dollar of assets, fluctuated within a range of -3.91% to 7.71% over the past quarters. The highest values were observed in the latter half of 2023 and the first half of 2024, indicating improved operational efficiency during those periods.
- Return on assets (ROA), a broader measure of overall profitability relative to total assets, displayed a wide variance from -6.41% to 13.13%. The company experienced negative ROA values in some quarters, suggesting inefficiencies in asset utilization, while positive values in profitable quarters indicate effective management of assets to generate earnings.
- Return on total capital, reflecting the return generated for all providers of capital (debt and equity), showed fluctuations from -7.42% to 18.86%. The negative values during certain periods indicate the company may not have effectively utilized its total capital to generate returns for shareholders and debt holders.
- Return on equity (ROE), representing profitability from the shareholders' perspective, ranged from -12.79% to 25.33%. The negative ROE values in some quarters point to the company's challenges in generating returns for its shareholders, while positive values in profitable quarters indicate the ability to provide a return on shareholders' equity.
In conclusion, Pacira BioSciences, Inc. has shown inconsistent profitability performance across different profitability ratios, indicating areas that may need improvement in terms of operational efficiency, asset utilization, and return to capital providers.